• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Hybrid contact lens created for keratoconus

Article

SynergEyes Inc. recently introduced a new contact lens (CL) design (ClearKone) for patients with keratoconus.

Key Points

Carlsbad, CA-SynergEyes Inc. recently introduced a new contact lens (CL) design (ClearKone) for patients with keratoconus. The design is optimized to vault the predominant irregularities of the keratoconic cornea, effectively restoring vision to a majority of patients with irregular corneas, according to the company.

The new design uses hybrid technology to make a lens with the visual clarity of a high-oxygen rigid gas permeable CL and the comfort and convenience of a soft lens, according to the company.

"SynergEyes recognized the need to develop a hybrid CL design that could fit a much broader spectrum of keratoconus patients, including oval cones, highly advanced central cones, decentered cones, and-depending on the specifics of the case-globus keratoconus and pellucid marginal degeneration," said Kellie Kaseburg, vice president of global marketing for SynergEyes.

Related Videos
Jacobi Cleaver, OD, FAAO
Jade Coats, OD, overviews a lecture on ocular pain and patient care
Jade Coats, OD, outlines two poster presentations she gave on a novel lipid-containing eye drop at the AOA Optometry's Meeting
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Lorraine Provencher, MD, presenting slides
Megan Cavet, PhD
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
© 2024 MJH Life Sciences

All rights reserved.